{
    "organizations": [],
    "uuid": "caacbfc11ac4d5b7b333c5dc6e07fe794b7a0975",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/01/pr-newswire-c-o-r-r-e-c-t-i-o-n--curis-inc.html",
    "ord_in_thread": 0,
    "title": "/C O R R E C T I O N -- Curis, Inc./",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "In the news release, Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018, issued 01-Mar-2018 by Curis, Inc. over PR Newswire, we are advised by the company that the dial-in numbers in the second paragraph have been updated. The complete, corrected release follows:\nCuris to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018\nLEXINGTON, Mass., March 1, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and year-end 2017 financial results on Thursday, March 8, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EST.\nTo access the live conference call, please dial 1-877-870-4263 from the United States or 1-412-317-0790 from other locations, shortly before 8:30 a.m. EST. A corresponding webcast of the conference call can be accessed by visiting https://www.webcaster4.com/Webcast/Page/1827/24814 . The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.\nAbout Curis, Inc.\nCuris is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing ErivedgeÂ® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com .\nView original content: http://www.prnewswire.com/news-releases/curis-to-release-fourth-quarter-and-year-end-2017-financial-results-and-hold-conference-call-on-march-8-2018-300606270.html\nSOURCE Curis, Inc.",
    "published": "2018-03-01T15:00:00.000+02:00",
    "crawled": "2018-03-01T17:05:31.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "news",
        "release",
        "curis",
        "release",
        "fourth",
        "quarter",
        "financial",
        "result",
        "hold",
        "conference",
        "call",
        "march",
        "issued",
        "curis",
        "pr",
        "newswire",
        "advised",
        "company",
        "number",
        "second",
        "paragraph",
        "updated",
        "complete",
        "corrected",
        "release",
        "follows",
        "curis",
        "release",
        "fourth",
        "quarter",
        "financial",
        "result",
        "hold",
        "conference",
        "call",
        "march",
        "lexington",
        "march",
        "curis",
        "nasdaq",
        "cris",
        "biotechnology",
        "company",
        "focused",
        "development",
        "commercialization",
        "innovative",
        "effective",
        "therapeutic",
        "treatment",
        "cancer",
        "today",
        "announced",
        "company",
        "release",
        "fourth",
        "quarter",
        "financial",
        "result",
        "thursday",
        "march",
        "financial",
        "market",
        "open",
        "company",
        "management",
        "also",
        "host",
        "conference",
        "call",
        "day",
        "est",
        "access",
        "live",
        "conference",
        "call",
        "please",
        "dial",
        "united",
        "state",
        "location",
        "shortly",
        "est",
        "corresponding",
        "webcast",
        "conference",
        "call",
        "accessed",
        "visiting",
        "http",
        "conference",
        "call",
        "also",
        "accessed",
        "curis",
        "website",
        "investor",
        "section",
        "curis",
        "curis",
        "biotechnology",
        "company",
        "focused",
        "development",
        "commercialization",
        "innovative",
        "effective",
        "drug",
        "candidate",
        "treatment",
        "human",
        "cancer",
        "including",
        "investigated",
        "clinical",
        "study",
        "patient",
        "lymphoma",
        "solid",
        "tumor",
        "curis",
        "also",
        "engaged",
        "broad",
        "collaboration",
        "aurigene",
        "area",
        "precision",
        "oncology",
        "part",
        "collaboration",
        "curis",
        "exclusive",
        "license",
        "oral",
        "small",
        "molecule",
        "dual",
        "antagonist",
        "pd1",
        "vista",
        "including",
        "antagonist",
        "oral",
        "small",
        "molecule",
        "dual",
        "antagonist",
        "pd1",
        "tim3",
        "including",
        "antagonist",
        "well",
        "molecule",
        "designed",
        "inhibit",
        "irak4",
        "kinase",
        "including",
        "currently",
        "undergoing",
        "testing",
        "phase",
        "trial",
        "patient",
        "advanced",
        "solid",
        "tumor",
        "lymphoma",
        "currently",
        "undergoing",
        "testing",
        "phase",
        "trial",
        "patient",
        "lymphoma",
        "curis",
        "also",
        "party",
        "collaboration",
        "genentech",
        "member",
        "roche",
        "group",
        "genentech",
        "roche",
        "commercializing",
        "treatment",
        "advanced",
        "basal",
        "cell",
        "carcinoma",
        "information",
        "visit",
        "curis",
        "website",
        "view",
        "original",
        "content",
        "http",
        "source",
        "curis",
        "inc"
    ]
}